Abstract
At diagnosis, Alzheimers disease (AD) brains are extensively burdened with plaques and tangles and display a degree of synaptic failure most likely beyond therapeutic treatment. It is therefore crucial to identify early pathological events in the progression of the disease. While it is not currently feasible to identify and study early, pre-clinical stages of AD, transgenic (Tg) models offer a valuable tool in this regard. Here we investigated cognitive, structural and biochemical CNS alterations occurring in our newly developed McGill-Thyl-APP Tg mice (over-expressing the human amyloid precursor protein with the Swedish and Indiana mutations) prior to extracellular plaque deposition. Pre-plaque, 3-month old Tg mice already displayed cognitive deficits concomitant with reorganization of cortical cholinergic pre-synaptic terminals. Conformational specific antibodies revealed the early appearance of intracellular amyloid β (Aβ)-oligomers and fibrillar oligomers in pyramidal neurons of cerebral cortex and hippocampus. At the same age, the cortical levels of insulin degrading enzyme -a well established Aβ-peptidase, were found to be significantly down-regulated. Our results suggest that, in the McGill-Thy1-APP Tg model, functional, structural and biochemical alterations are already present in the CNS at early, pre-plaque stages of the pathology. Accumulation of intraneuronal neurotoxic Aβ-oligomers (possibly caused by a failure in the clearance machinery) is likely to be the culprit of such early, pre-plaque pathology. Similar neuronal alterations might occur prior to clinical diagnosis in AD, during a yet undefined ‘latent’ stage. A better understanding of such pre-clinical AD might yield novel therapeutic targets and or diagnostic tools.
Keywords: Aβ-oligomers, ADDLs, cholinergic synapse, IDE, neprilysin, pre-clinical Alzheimer's disease, Dementia, Memory loss, Fibrilliar amyloid beta peptide, Western blotting, monoclonal antbody, Morris Water Maze, Dystrophic neurites, hippocampus
Current Alzheimer Research
Title: Transgenic Mice as a Model of Pre-Clinical Alzheimers Disease
Volume: 8 Issue: 1
Author(s): M. T. Ferretti, V. Partridge, W. C. Leon , F. Canneva, S. Allard, D. N. Arvanitis, F. Vercauteren, D. Houle , A. Ducatenzeiler , W. L. Klein , C. G. Glabe, M. Szyf and A. C. Cuello
Affiliation:
Keywords: Aβ-oligomers, ADDLs, cholinergic synapse, IDE, neprilysin, pre-clinical Alzheimer's disease, Dementia, Memory loss, Fibrilliar amyloid beta peptide, Western blotting, monoclonal antbody, Morris Water Maze, Dystrophic neurites, hippocampus
Abstract: At diagnosis, Alzheimers disease (AD) brains are extensively burdened with plaques and tangles and display a degree of synaptic failure most likely beyond therapeutic treatment. It is therefore crucial to identify early pathological events in the progression of the disease. While it is not currently feasible to identify and study early, pre-clinical stages of AD, transgenic (Tg) models offer a valuable tool in this regard. Here we investigated cognitive, structural and biochemical CNS alterations occurring in our newly developed McGill-Thyl-APP Tg mice (over-expressing the human amyloid precursor protein with the Swedish and Indiana mutations) prior to extracellular plaque deposition. Pre-plaque, 3-month old Tg mice already displayed cognitive deficits concomitant with reorganization of cortical cholinergic pre-synaptic terminals. Conformational specific antibodies revealed the early appearance of intracellular amyloid β (Aβ)-oligomers and fibrillar oligomers in pyramidal neurons of cerebral cortex and hippocampus. At the same age, the cortical levels of insulin degrading enzyme -a well established Aβ-peptidase, were found to be significantly down-regulated. Our results suggest that, in the McGill-Thy1-APP Tg model, functional, structural and biochemical alterations are already present in the CNS at early, pre-plaque stages of the pathology. Accumulation of intraneuronal neurotoxic Aβ-oligomers (possibly caused by a failure in the clearance machinery) is likely to be the culprit of such early, pre-plaque pathology. Similar neuronal alterations might occur prior to clinical diagnosis in AD, during a yet undefined ‘latent’ stage. A better understanding of such pre-clinical AD might yield novel therapeutic targets and or diagnostic tools.
Export Options
About this article
Cite this article as:
T. Ferretti M., Partridge V., C. Leon W., Canneva F., Allard S., N. Arvanitis D., Vercauteren F., Houle D., Ducatenzeiler A., L. Klein W., G. Glabe C., Szyf M. and C. Cuello A., Transgenic Mice as a Model of Pre-Clinical Alzheimers Disease, Current Alzheimer Research 2011; 8 (1) . https://dx.doi.org/10.2174/156720511794604561
DOI https://dx.doi.org/10.2174/156720511794604561 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy
Current Gene Therapy Nutraceutical: A Drug, Dietary Supplement and Food Ingredient
Current Pharmacogenomics and Personalized Medicine AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Intracompartmental Delivery of CNTF as Therapy for Huntingtons Disease and Retinitis Pigmentosa
Current Gene Therapy The Complex Inter-Relationship Between Diabetes and Schizophrenia
Current Diabetes Reviews (-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer’s Disease
Current Alzheimer Research Antioxidant Agents in Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Nanomedicinal Approach of Getting Across the Brood-Brain Barrier with Nanomedicinal Nanoparticles
Current Medicinal Chemistry Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Methodologies to Assess Brain Drug Delivery in Lead Optimization
Current Topics in Medicinal Chemistry Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research
Current Drug Abuse Reviews Post Dural Puncture Headache and Hypertension
Current Hypertension Reviews Non-enzymatic Glycation of Almond Cystatin Leads to Conformational Changes and Altered Activity
Protein & Peptide Letters Visual Spatial Attention Training Improve Spatial Attention and Motor Control for Unilateral Neglect Patients
CNS & Neurological Disorders - Drug Targets Is Covalently Crosslinked Aβ Responsible for Synaptotoxicity in Alzheimers Disease?
Current Alzheimer Research Ionotropic Glutamate Receptors & CNS Disorders
CNS & Neurological Disorders - Drug Targets Change in INSR, APBA2 and IDE Gene Expressions in Brains of Alzheimer's Disease Patients
Current Alzheimer Research Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimers Disease, and its Relationship with Cognitive Impairment
Current Alzheimer Research Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management
Current Diabetes Reviews